CY1112638T1 - Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον - Google Patents
Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsονInfo
- Publication number
- CY1112638T1 CY1112638T1 CY20121100267T CY121100267T CY1112638T1 CY 1112638 T1 CY1112638 T1 CY 1112638T1 CY 20121100267 T CY20121100267 T CY 20121100267T CY 121100267 T CY121100267 T CY 121100267T CY 1112638 T1 CY1112638 T1 CY 1112638T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rarkinson
- nurr
- indolium
- producers
- activators
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-O 1H-indol-1-ium Chemical compound C1=CC=C2[NH2+]C=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-O 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
- -1 isopropyl (1-methylethyl) Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αφορά μια λαμβανόμενη από ινδόλιο ένωση, ιδιαίτερα χρήσιμη στη θεραπεία και που χαρακτηρίζεται από το ότι η ένωση επιλέγεται μεταξύ iii) των ενώσεων του τύπου (Ι), όπου: το R1 είναι ένα άτομο αλογόνου ή τριφθορομεθυλο ομάδα, το R2 είναι ένα άτομο υδρογόνου ή (C1-C4) αλκυλ ομάδα, το R3 είναι ένα ισοπροπύλ(1-μεθυλαιθυλ) ομάδα ή τ- βουτυλ-(1,1-διμεθυλοαιθυλ) και n= 3 ή 4. Η εφεύρεση αφορά περαιτέρω τα φαρμακευτικώς αποδεκτά άλατα των εν λόγω ενώσεων του τύπου (Ι). Η εφεύρεση μπορεί να χρησιμοποιηθεί για τη θεραπεία των νευροεκφυλιστικών νόσων και ιδίως της νόσου του Parkinson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0854712A FR2933609B1 (fr) | 2008-07-10 | 2008-07-10 | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson. |
EP09784501A EP2300424B1 (fr) | 2008-07-10 | 2009-07-09 | Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112638T1 true CY1112638T1 (el) | 2016-02-10 |
Family
ID=40297845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100267T CY1112638T1 (el) | 2008-07-10 | 2012-03-14 | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον |
Country Status (28)
Country | Link |
---|---|
US (1) | US8575210B2 (el) |
EP (1) | EP2300424B1 (el) |
JP (1) | JP5396650B2 (el) |
KR (1) | KR101606184B1 (el) |
CN (1) | CN102112441B (el) |
AR (1) | AR072718A1 (el) |
AT (1) | ATE541831T1 (el) |
AU (1) | AU2009269842B2 (el) |
BR (1) | BRPI0915627A8 (el) |
CA (1) | CA2730302C (el) |
CY (1) | CY1112638T1 (el) |
DK (1) | DK2300424T3 (el) |
EA (1) | EA018079B1 (el) |
ES (1) | ES2381180T3 (el) |
FR (1) | FR2933609B1 (el) |
HK (1) | HK1154852A1 (el) |
HR (1) | HRP20120231T1 (el) |
IL (1) | IL210386A (el) |
MX (1) | MX2011000353A (el) |
MY (1) | MY155959A (el) |
PL (1) | PL2300424T3 (el) |
PT (1) | PT2300424E (el) |
SA (1) | SA109300453B1 (el) |
SI (1) | SI2300424T1 (el) |
TW (1) | TWI414289B (el) |
UA (1) | UA102397C2 (el) |
WO (1) | WO2010004221A2 (el) |
ZA (1) | ZA201100041B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2955108B1 (fr) * | 2010-01-08 | 2012-03-16 | Fournier Lab Sa | Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
KR101964889B1 (ko) | 2017-11-17 | 2019-04-02 | 한국생명공학연구원 | 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
CA3138439C (en) | 2017-11-15 | 2023-05-23 | Korea Research Institute Of Bioscience And Biotechnology | Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound |
KR102059160B1 (ko) | 2017-11-15 | 2019-12-24 | 한국생명공학연구원 | 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
KR20240020098A (ko) | 2022-08-05 | 2024-02-14 | 엠테라파마 주식회사 | 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7348359B2 (en) * | 2001-03-14 | 2008-03-25 | Eli Lilly And Company | Retinoid X receptor modulators |
GB0119911D0 (en) * | 2001-08-15 | 2001-10-10 | Novartis Ag | Organic Compounds |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
EP1689389A4 (en) * | 2003-12-04 | 2009-06-17 | Nat Health Research Institutes | Indole compounds |
FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2903107B1 (fr) | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
FR2903105A1 (fr) | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
FR2903106B1 (fr) | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
-
2008
- 2008-07-10 FR FR0854712A patent/FR2933609B1/fr not_active Expired - Fee Related
-
2009
- 2009-07-08 SA SA109300453A patent/SA109300453B1/ar unknown
- 2009-07-08 AR ARP090102577A patent/AR072718A1/es unknown
- 2009-07-09 CA CA2730302A patent/CA2730302C/fr not_active Expired - Fee Related
- 2009-07-09 AT AT09784501T patent/ATE541831T1/de active
- 2009-07-09 AU AU2009269842A patent/AU2009269842B2/en not_active Ceased
- 2009-07-09 US US13/003,554 patent/US8575210B2/en not_active Expired - Fee Related
- 2009-07-09 DK DK09784501.0T patent/DK2300424T3/da active
- 2009-07-09 EP EP09784501A patent/EP2300424B1/fr not_active Not-in-force
- 2009-07-09 EA EA201170150A patent/EA018079B1/ru not_active IP Right Cessation
- 2009-07-09 MX MX2011000353A patent/MX2011000353A/es active IP Right Grant
- 2009-07-09 PT PT09784501T patent/PT2300424E/pt unknown
- 2009-07-09 KR KR1020117000129A patent/KR101606184B1/ko not_active IP Right Cessation
- 2009-07-09 CN CN2009801269277A patent/CN102112441B/zh not_active Expired - Fee Related
- 2009-07-09 BR BRPI0915627A patent/BRPI0915627A8/pt not_active IP Right Cessation
- 2009-07-09 ES ES09784501T patent/ES2381180T3/es active Active
- 2009-07-09 UA UAA201100224A patent/UA102397C2/ru unknown
- 2009-07-09 WO PCT/FR2009/051372 patent/WO2010004221A2/fr active Application Filing
- 2009-07-09 MY MYPI2011000084A patent/MY155959A/en unknown
- 2009-07-09 JP JP2011517215A patent/JP5396650B2/ja not_active Expired - Fee Related
- 2009-07-09 SI SI200930209T patent/SI2300424T1/sl unknown
- 2009-07-09 PL PL09784501T patent/PL2300424T3/pl unknown
- 2009-07-10 TW TW098123503A patent/TWI414289B/zh not_active IP Right Cessation
-
2010
- 2010-12-30 IL IL210386A patent/IL210386A/en not_active IP Right Cessation
-
2011
- 2011-01-03 ZA ZA2011/00041A patent/ZA201100041B/en unknown
- 2011-08-29 HK HK11109072.9A patent/HK1154852A1/xx not_active IP Right Cessation
-
2012
- 2012-03-13 HR HR20120231T patent/HRP20120231T1/hr unknown
- 2012-03-14 CY CY20121100267T patent/CY1112638T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
NZ547615A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
ATE517882T1 (de) | Chinolinderivate | |
EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
CY1115533T1 (el) | Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr | |
EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
DK1780197T3 (da) | 5-Substituerede 2-phenylamino-benzamider som MEK-inhibitorer | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
EA200700099A1 (ru) | Производные пиридина | |
TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
DE602008001725D1 (de) | 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
NO20082112L (no) | 3-Amino-2-arylpropylazaindoler og deres anvendelse | |
CY1109376T1 (el) | Παραγωγα υδαντοϊνης χρησιμα ως αναστολεις μεταλλοπρωτεϊνασης | |
RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
DE602006014022D1 (de) | 5-substituierte indol-2-carbonsäureamidderivate |